{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:15:22Z","timestamp":1792426522559,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.psc.2022.11.005","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T19:21:49Z","timestamp":1672860109000},"page":"107-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Pharmacological Treatment of Obsessive-Compulsive Disorder"],"prefix":"10.1016","volume":"46","author":[{"given":"Christopher","family":"Pittenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.psc.2022.11.005_bib1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.euroneuro.2016.02.006","article-title":"The cost and impact of compulsivity: a research perspective","volume":"26","author":"Hollander","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.psc.2022.11.005_bib2","series-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","first-page":"57","article-title":"Quality of life and psychosocial functioning in OCD","author":"Boisseau","year":"2017"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.psc.2022.11.005_bib4","series-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","first-page":"35","article-title":"Epidemiology, comorbidity, and burden of OCD","author":"Torres","year":"2017"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.psc.2022.11.005_bib6","series-title":"American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders : DSM-5","year":"2013"},{"key":"10.1016\/j.psc.2022.11.005_bib7","series-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","first-page":"669","article-title":"The dynamics of obsessive-compulsive disorder: A heuristic framework","author":"Pittenger","year":"2017"},{"key":"10.1016\/j.psc.2022.11.005_bib8","series-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","first-page":"129","article-title":"Variable insight in OCD","author":"Hamblin","year":"2017"},{"issue":"8","key":"10.1016\/j.psc.2022.11.005_bib9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis","volume":"3","author":"Skapinakis","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"7 Suppl","key":"10.1016\/j.psc.2022.11.005_bib10","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2022.11.005_bib11","series-title":"Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder","volume":"31","year":"2006"},{"issue":"4","key":"10.1016\/j.psc.2022.11.005_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J Biol Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.psc.2022.11.005_bib13","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.4103\/0019-5545.196976","article-title":"Clinical practice guidelines for Obsessive-Compulsive Disorder","volume":"59","author":"Janardhan Reddy","year":"2017","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.psc.2022.11.005_bib14","first-page":"1","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD","author":"Bandelow","year":"2022","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.psc.2022.11.005_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113853","article-title":"Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder","volume":"300","author":"Pittenger","year":"2021","journal-title":"Psychiatry Res"},{"issue":"4","key":"10.1016\/j.psc.2022.11.005_bib16","first-page":"457","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis","volume":"19","author":"Skapinakis","year":"2021","journal-title":"Focus (Am Psychiatr Publ)."},{"key":"10.1016\/j.psc.2022.11.005_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/7854_2020_204","article-title":"Pharmacotherapeutic strategies and new targets in OCD","volume":"49","author":"Pittenger","year":"2021","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib18","first-page":"CD001765","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","author":"Soomro","year":"2008","journal-title":"Cochrane database Syst Rev"},{"issue":"4","key":"10.1016\/j.psc.2022.11.005_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4088\/JCP.v67n0411","article-title":"Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review","volume":"67","author":"Dell'Osso","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","article-title":"Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2022.11.005_bib21","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1176\/appi.ajp.160.11.1919","article-title":"Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder","volume":"160","author":"Geller","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0897190015624862","article-title":"Should we be worried about QTc prolongation using citalopram? A review","volume":"30","author":"Hutton","year":"2017","journal-title":"J\u00a0Pharm Pract"},{"key":"10.1016\/j.psc.2022.11.005_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/7854_2020_205","article-title":"Pharmacogenetics of obsessive-compulsive disorder: an evidence-update","volume":"49","author":"Zai","year":"2021","journal-title":"Curr Top Behav Neurosci"},{"issue":"8","key":"10.1016\/j.psc.2022.11.005_bib24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose\u2013response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2022.11.005_bib25","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.4088\/JCP.14r09758","article-title":"Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis","volume":"77","author":"Issari","year":"2016","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"6\u20137","key":"10.1016\/j.psc.2022.11.005_bib26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.euroneuro.2006.11.005","article-title":"Escitalopram prevents relapse of obsessive-compulsive disorder","volume":"17","author":"Fineberg","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2022.11.005_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004850-199711000-00003","article-title":"A\u00a02-year study of sertraline in the treatment of obsessive-compulsive disorder","volume":"12","author":"Rasmussen","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2022.11.005_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study","volume":"23","author":"Stein","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.psc.2022.11.005_bib29","series-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","first-page":"443","article-title":"Standard evidence-based pharmacological treatment for OCD","author":"Reid","year":"2017"},{"issue":"2","key":"10.1016\/j.psc.2022.11.005_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00406-004-0544-8","article-title":"Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial","volume":"255","author":"Rufer","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib31","first-page":"167","article-title":"Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)","volume":"32","author":"Ravizza","year":"1996","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamapsychiatry.2021.3997","article-title":"Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure\/response prevention augmentation: a randomized clinical trial","volume":"79","author":"Foa","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2022.11.005_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/da.20003","article-title":"Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder","volume":"19","author":"Simpson","year":"2004","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib34","first-page":"36","article-title":"Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder","volume":"25","author":"DeVeaugh-Geiss","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.psc.2022.11.005_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.136.1.1","article-title":"Clomipramine and exposure for obsessive-compulsive rituals: i","volume":"136","author":"Marks","year":"1980","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.psc.2022.11.005_bib36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archpsyc.1983.04390010015002","article-title":"Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline","volume":"40","author":"Insel","year":"1983","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145704004675","article-title":"Evidence-based pharmacotherapy of obsessive-compulsive disorder","volume":"8","author":"Fineberg","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0364-7722(81)90077-1","article-title":"Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis","volume":"5","author":"Ananth","year":"1981","journal-title":"Prog Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.psc.2022.11.005_bib39","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cpr.2004.08.004","article-title":"A\u00a0multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder","volume":"24","author":"Eddy","year":"2004","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archpsyc.1995.03950130053006","article-title":"Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis","volume":"52","author":"Greist","year":"1995","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0193-953X(05)70186-6","article-title":"Pharmacotherapy for obsessive-compulsive disorder","volume":"23","author":"Hollander","year":"2000","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.psc.2022.11.005_bib42","series-title":"Tripp J. Clomipramine","author":"Wilson","year":"2022"},{"issue":"72","key":"10.1016\/j.psc.2022.11.005_bib43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-3-211-73574-9_35","article-title":"Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice","author":"Pfuhlmann","year":"2007","journal-title":"J\u00a0Neural Transm Suppl"},{"issue":"6","key":"10.1016\/j.psc.2022.11.005_bib44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003088-199120060-00002","article-title":"Clinical pharmacokinetics of clomipramine","volume":"20","author":"Balant-Gorgia","year":"1991","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.psc.2022.11.005_bib45","first-page":"257","article-title":"Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data","volume":"57","author":"Szegedi","year":"1996","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib46","first-page":"150","article-title":"Retrospective Review of fluvoxamine-clomipramine combination therapy in obsessive-compulsive disorder in children and adolescents","volume":"30","author":"Fung","year":"2021","journal-title":"J\u00a0Can Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2022.11.005_bib47","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial","volume":"70","author":"Simpson","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2022.11.005_bib48","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics","volume":"51","author":"McDougle","year":"1994","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.psc.2022.11.005_bib49","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A\u00a0systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2022.11.005_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euroneuro.2006.07.002","article-title":"Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials","volume":"17","author":"Skapinakis","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.psc.2022.11.005_bib51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2022.11.005_bib52","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1176\/ajp.152.12.1812","article-title":"Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder","volume":"152","author":"McDougle","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","article-title":"Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases","volume":"27","author":"Lykouras","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib54","first-page":"106","article-title":"Antipsychotic Monotherapy in Obsessive-Compulsive Disorder","volume":"34","author":"Crapanzano","year":"2022","journal-title":"Psychiatr Danub"},{"issue":"9","key":"10.1016\/j.psc.2022.11.005_bib55","doi-asserted-by":"crossref","first-page":"pyv047","DOI":"10.1093\/ijnp\/pyv047","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"18","author":"Dold","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.psc.2022.11.005_bib56","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","article-title":"Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials","volume":"27","author":"Kishi","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.psc.2022.11.005_bib57","first-page":"1","article-title":"Efficacy and safety\/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis","author":"Kishimoto","year":"2022","journal-title":"Psychol Med"},{"issue":"1","key":"10.1016\/j.psc.2022.11.005_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00004850-200101000-00004","article-title":"Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder","volume":"16","author":"Maina","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib59","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.psc.2022.11.005_bib60","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer's disease facts and figures","volume":"18","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib61","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/104012371803000307","article-title":"The use of memantine in neuropsychiatric disorders: an overview","volume":"30","author":"Lu","year":"2018","journal-title":"Ann Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.psc.2022.11.005_bib62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0043-120268","article-title":"Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial","volume":"51","author":"Modarresi","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.psc.2022.11.005_bib63","doi-asserted-by":"crossref","first-page":"19f13163","DOI":"10.4088\/JCP.19f13163","article-title":"Augmentation with memantine in obsessive-compulsive disorder","volume":"80","author":"Andrade","year":"2019","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2022.11.005_bib64","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.psychres.2019.06.020","article-title":"Efficacy and tolerability of riluzole in psychiatric disorders: a systematic review and preliminary meta-analysis","volume":"278","author":"de Boer","year":"2019","journal-title":"Psychiatry Res"},{"issue":"9","key":"10.1016\/j.psc.2022.11.005_bib65","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00023210-200822090-00004","article-title":"Riluzole in the treatment of mood and anxiety disorders","volume":"22","author":"Pittenger","year":"2008","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.psc.2022.11.005_bib66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/JCP.0b013e3181727548","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up","volume":"28","author":"Pittenger","year":"2008","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2022.11.005_bib67","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.psc.2022.11.005_bib68","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial","volume":"76","author":"Pittenger","year":"2015","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.psc.2022.11.005_bib69","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/pcn.12394","article-title":"Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study","volume":"70","author":"Emamzadehfard","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"10.1016\/j.psc.2022.11.005_bib70","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/npp.2013.343","article-title":"12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder","volume":"39","author":"Grant","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.psc.2022.11.005_bib71","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2022.11.005_bib72","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psc.2022.11.005_bib73","doi-asserted-by":"crossref","first-page":"102183","DOI":"10.1016\/j.ajp.2020.102183","article-title":"Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder","volume":"52","author":"Sharma","year":"2020","journal-title":"Asian J Psychiatr"},{"issue":"2","key":"10.1016\/j.psc.2022.11.005_bib74","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/JCP.0000000000000659","article-title":"Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder","volume":"37","author":"Adams","year":"2017","journal-title":"J\u00a0Clin Psychopharmacol"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X22001022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X22001022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:41:45Z","timestamp":1759282905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X22001022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0193953X22001022"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2022.11.005","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pharmacological Treatment of Obsessive-Compulsive Disorder","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}